Craxì, L <br/><br/>
Prioritization of high-cost new drugs for HCV: making sustainability ethical.  [electronic resource] 

 -  European review for medical and pharmacological sciences  2016 
 - 1044-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>2284-0729 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antiviral Agents--economics<br/>Carcinoma, Hepatocellular--drug therapy<br/>Drug Costs--ethics<br/>Drug Therapy, Combination<br/>Health Priorities--economics<br/>Hepacivirus<br/>Hepatitis C--drug therapy<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon-alpha--economics<br/>Liver Neoplasms--drug therapy<br/>Quality of Life